Haleon (LON:HLN) Now Covered by Analysts at HSBC

Stock analysts at HSBC assumed coverage on shares of Haleon (LON:HLN) in a research note issued on Thursday, Marketbeat.com reports. The brokerage set a “buy” rating on the stock.

Separately, Barclays lowered their price target on Haleon from GBX 390 ($4.85) to GBX 383 ($4.77) and set an “overweight” rating on the stock in a research report on Tuesday, April 9th.

Haleon Price Performance

Shares of LON:HLN opened at GBX 325.80 ($4.06) on Thursday. The company’s fifty day moving average price is GBX 324.40 and its 200-day moving average price is GBX 326.71. The company has a debt-to-equity ratio of 57.42, a current ratio of 1.04 and a quick ratio of 0.93. The firm has a market capitalization of £29.75 billion and a price-to-earnings ratio of 2,961.82. Haleon has a one year low of GBX 306.80 ($3.82) and a one year high of GBX 357.65 ($4.45).

Insider Transactions at Haleon

In related news, insider Tobias Hestler sold 23,564 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of GBX 329 ($4.10), for a total transaction of £77,525.56 ($96,508.85). Company insiders own 22.53% of the company’s stock.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.